Skip to main content
    M

    Mediwound Ltd (MDWD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.91
    -0.31 (-2.54%)

    Market Cap: $153.76M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +53.23%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.73
    Range$-0.92 - $-0.62
    5 analysts
    EPS Revisions
    2
    0
    7d
    2
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.71-2.8%
    60d ago$-0.71-2.8%
    30d ago$-0.730.0%
    7d ago$-0.730.0%
    Current$-0.73
    Revenue Consensus
    $7M
    Range$6M - $8M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.07
    Range$-0.55 - $0.18
    5 analysts
    Revenue Consensus
    $11M
    Range$8M - $13M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.73---
    Jun 26
    Reported Aug 13
    		$-0.77$-0.76-1.32%Miss+37.4%
    Mar 26
    Reported May 27
    		$-0.23N/A+65.15%Beat-228.6%
    Dec 25
    Reported Mar 5
    		$-0.56$-0.61+8.20%Beat-55.6%
    Sep 25
    Reported Nov 20
    		$-0.24N/A+71.08%Beat+75.5%
    Jun 25
    Reported Aug 14
    		$-1.23$-0.57-115.79%Miss-80.9%
    Mar 25
    Reported May 21
    		$-0.07N/A+89.39%Beat+93.3%
    Dec 24
    Reported Mar 19
    		$-0.36$-0.59+38.98%Beat-89.5%
    Sep 24
    Reported Nov 26
    		$-0.98$-0.44-122.73%Miss-308.3%
    Jun 24
    Reported Aug 14
    		$-0.68$-0.42-61.90%Miss-780.0%
    Mar 24
    Reported May 29
    		$-1.05$-0.41-156.10%Miss-138.6%
    Dec 23
    Reported Mar 21
    		$-0.19$-0.23+17.39%Beat+83.9%
    Sep 23
    Reported Nov 21
    		$-0.24$-0.39+38.46%Beat+73.6%
    Jun 23
    Reported Aug 15
    		$0.10N/A+129.41%Beat+111.0%
    Mar 23
    Reported May 30
    		$-0.44$-0.43-2.33%Miss+47.6%
    Dec 22
    Reported Mar 16
    		$-1.18$-0.59-100.00%Miss-12.4%
    Sep 22
    Reported Nov 15
    		$-0.91$-0.68-33.82%Miss-8.3%
    Jun 22
    Reported Aug 9
    		$-0.91$-0.68-33.82%Miss-8.3%
    Mar 22
    Reported May 17
    		$-0.84$-0.76-10.53%Miss-20.0%
    Dec 21
    Reported Mar 17
    		$-1.05$-1.05+0.00%Beat-150.0%
    Sep 21
    Reported Nov 16
    		$-0.84$-0.90+6.67%Beat-71.4%
    Jun 21
    Reported Aug 10
    		$-0.84$-0.78-7.69%Miss-9.1%
    Mar 21
    Reported May 5
    		$-0.70$-0.81+13.58%Beat-11.1%
    Dec 20
    Reported Feb 25
    		$-0.42$-0.79+46.84%Beat+53.8%
    Sep 20
    Reported Nov 10
    		$-0.49$-0.67+26.87%Beat+36.4%
    Jun 20
    Reported Aug 6
    		$-0.77$-0.84+8.33%Beat-123.4%
    Mar 20
    Reported May 20
    		$-0.63$-1.00+37.00%Beat+40.0%
    Dec 19
    Reported Feb 25
    		$-0.91$-0.73-24.66%Miss-160.0%
    Sep 19
    Reported Nov 14
    		$-0.77$-0.91+15.38%Beat+0.0%
    Jun 19
    Reported Aug 13
    		$3.29$-0.18+1927.78%Beat+413.3%
    Mar 19
    Reported May 21
    		$-1.05$-0.98-7.14%Miss+11.8%
    Dec 18
    Reported Mar 25
    		$-0.35N/A+66.98%Beat+44.4%
    Sep 18
    Reported Nov 13
    		$-0.77$-1.37+43.80%Beat+31.3%
    Jun 18
    Reported Aug 7
    		$-1.05$-1.37+23.36%Beat+25.0%
    Mar 18
    Reported May 10
    		$-1.19$-0.94-26.60%Miss+15.0%
    Dec 17
    Reported Mar 19
    		$-0.63$-1.19+47.06%Beat+0.0%
    Sep 17
    Reported Nov 16
    		$-1.12$-1.33+15.79%Beat-
    Jun 17
    Reported Aug 3
    		$-1.40$-1.37-2.19%Miss-
    Mar 17
    Reported May 8
    		$-1.40$-1.18-18.64%Miss-
    Dec 16
    Reported Feb 21
    		$-0.63N/A+63.79%Beat-

    Key Metrics

    Valuation
    P/E Ratio-6.62EV/EBITDAN/A
    Price/FCF-5.41xFCF Yield-18.50%
    Profitability
    Profit Margin-170.10%Operating Margin-305.90%
    ROE-72.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.32xQuick Ratio2.09x
    Trading Statistics
    Beta0.09Avg Volume71.00K
    52-Week High$20.0352-Week Low$11.90

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.83
    SMA 20$13.26
    SMA 50$13.35
    SMA 200$15.58
    EMA 10$12.69
    EMA 20$13.02
    EMA 50$13.43
    EMA 200$15.13

    MACD

    Line: -0.33Signal: -0.16Hist: -0.17

    ADX

    ADX: 23.3+DI: 8.6-DI: 26.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$13.53

    Bollinger Bands

    Upper Band$14.50
    Lower Band$12.01
    %B Position1879%(Upper)
    Band Width-0.04

    RSI (14-Day)

    Oversold
    28.6

    Momentum Oscillators

    Stoch %K4.8
    Stoch %D6.2
    Williams %R-99.5
    ROC (10d)-13.5%
    Momentum-1.86
    CCI (20d)-183.1
    MFI (14d)22.9

    Volatility Measures

    ATR (14d)$0.47(3.9%)
    StdDev (20d)0.62
    Hist Vol29.9%(Moderate)

    Volume Flow

    VWAP$12.05
    OBV652.4K
    AD Line-2.8M
    CMF (20d)-0.189

    Volume Metrics

    Avg Vol (20d)70.1K
    Vol Ratio1.3x
    VWMA (20d)$13.18

    Pivot Points

    R3$12.93
    R2$12.77
    R1$12.50
    Pivot Point$12.34
    S1$12.07
    S2$11.91
    S3$11.64

    Advanced Oscillators

    TSI-21.25
    Ultimate Osc21.7
    KST-29.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.09M$1.48M$1.87M$5.43M$5.71M$3.96M$5.84M$4.36M$5.06M$4.96M$5.34M$4.78M
    Cost of Revenue$2.75M$1.15M$1.59M$4.53M$4.37M$3.22M$4.94M$3.68M$4.62M$4.36M$4.62M$3.88M
    Gross Profit$337,000$323,000$278,000$896,000$1.34M$738,000$903,000$677,000$447,000$607,000$719,000$896,000
    Operating Expenses$9.79M$8.30M$8.09M$7.42M$7.06M$5.96M$6.99M$5.76M$4.93M$4.34M$4.61M$3.92M
    R&D$5.90M$5.18M$4.48M$3.46M$3.49M$2.89M$2.99M$2.52M$1.90M$1.47M$1.81M$1.53M
    SG&A$3.89M$2.30M$3.85M$2.32M$2.10M$1.79M$4.04M$2.17M$1.81M$1.69M$6.77M$1.42M
    Operating Income$-9,458,000$-7,980,000$-7,813,000$-6,525,000$-5,716,000$-5,225,000$-6,083,000$-5,081,000$-4,484,000$-3,734,000$-3,894,000$-3,025,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$1.12M$0$0$0$7.99M$0$0$5.18M$2.40M$5.97M$5.97M$0
    Income Before Tax$-7,359,000$-2,969,000$-7,110,000$-2,599,000$-13,280,000$-721,000$-3,890,000$-10,261,000$-6,307,000$-9,705,000$-1,623,000$-2,148,000
    Income Tax Expense$33,000$-17,000$73,000$53,000$38,000$5,000$18,000$21,000$-2,000$24,000$120,000$48,000
    Net Income$-7,392,000$-2,952,000$-7,183,000$-2,652,000$-13,318,000$-726,000$-3,908,000$-10,282,000$-6,305,000$-9,729,000$-1,743,000$-2,196,000
    EBITDA$-9,056,000$-2,591,000$-5,174,000$-2,181,000$-4,893,000$-363,000$-15,715,000$-4,720,000$-3,545,000$-3,366,000$5.64M$-1,809,000
    EBIT$-9,458,000$-2,969,000$-5,864,000$-2,599,000$-5,287,000$-721,000$-16,112,000$-5,081,000$-3,902,000$-3,734,000$5.29M$-2,148,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MDWD

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    100.0%
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Precision Trading with Mediwound Ltd. (MDWD) Risk Zones

    This article from Stock Traders Daily provides a detailed analysis of Mediwound Ltd. (MDWD), highlighting weak sentiment across all time horizons supporting a short bias. It outlines three distinct AI-generated trading...

    Stock Traders Daily•10/12/26•Bearish

    Weekly Recap: DoD funding for NexoBrid and VALUE Phase III reassessment

    MediWound Ltd. (MDWD) has secured $3.3 million in non-dilutive DoD funding to advance a room-temperature NexoBrid formulation towards IND readiness, increasing the program budget to $21.8 million. Concurrently...

    TradingView•9/28/26•Bullish

    TD Cowen reiterates MediWound stock rating ahead of trial data

    TD Cowen has reiterated a Buy rating and a $25.00 price target for MediWound Ltd (NASDAQ:MDWD), citing an attractive setup ahead of the Phase 3 VALUE interim analysis. The firm believes positive EscharEx data could...

    Investing.com•9/24/26•Bullish

    MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

    MediWound (MDWD) has secured an additional $3.3 million in funding from the U.S. Department of War, bringing the total program budget to $21.8 million. This funding will advance the development...

    Stock Titan•9/23/26•Bullish

    MediWound receives $3.3M from DoD for NexoBrid development

    MediWound Ltd. has received an additional $3.3 million in non-dilutive funding from the U.S. Department of Defense to develop a room-temperature-stable formulation of NexoBrid...

    Investing.com•9/22/26•Bullish

    MDWD Valuation and Fair Value

    P/E
    -6.6x
    Forward P/E
    35.0x
    P/FCF
    -5.4x
    PEG
    -0.1x
    P/B
    4.3x
    See GNG's fair value

    MDWD Profitability: Margins, ROIC and FCF

    Gross margin
    15.5%
    Operating margin
    -305.9%
    Net margin
    -170.1%
    ROE
    -72.4%
    FCF margin
    -239.3%
    FCF yield
    -18.5%

    MDWD Competitors

    CompanyTicker
    OPTIMIZERx CorpOPRX
    Helius Medical Technologies Inc Class AHSDT
    Anbio Biotechnology Class A Ordinary SharesNNNN
    JIN MEDICAL INTERNATIONAL LTD. Ordinary SharesZJYL
    Compass Therapeutics Inc.CMPX
    Mersana Therapeutics IncMRSN
    Quipt Home Medical CorpQIPT
    Sound Point Meridian Capital, Inc.SPMC

    Sector: Healthcare

    MDWD Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    MDWD Bull Case vs Bear Case

    Bull case

    • 100.0% of MDWD's analyst ratings are Buy or Strong Buy.

    Bear case

    • MDWD has a -170.1% net profit margin.
    • MDWD's quarterly revenue changed -45.8% year over year.

    MDWD Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    4.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.73
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 3 down

    Frequently Asked Questions About MDWD

    Does MDWD pay dividends?

    Mediwound Ltd (MDWD) does not currently pay a regular dividend.

    What is MDWD's market cap?

    Mediwound Ltd (MDWD) has a market capitalization of $153.76M with a current stock price of $11.91.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In